Global Cervical Cancer Therapeutics Market 2023
The global cervical cancer therapeutics market was valued at USD 5.66 billion in 2022 and is projected to reach USD 7.14 billion by 2029, exhibiting a compound annual growth rate of 3.3% between 2023 and 2029.
The rising prevalence of cervical cancer worldwide is the predominant factor driving growth in this market. Cervical cancer originates from the uncontrolled division of abnormal cells in the cervix, primarily caused by high-risk strains of human papillomavirus (HPV) infection. China, United States, and Japan currently have the highest number of diagnosed cases.
Another major factor is the growing rate of HIV infection among women, as HIV-positive females have a 5-fold higher risk of contracting cervical cancer compared to the general population.
Early-stage cervical cancer is generally treated with surgery such as hysterectomy, while advanced metastatic disease requires chemotherapy and radiotherapy. Recent FDA approvals of immunotherapy drugs like Keytruda and Tivdak have transformed treatment paradigms, particularly in the U.S.
Widespread implementation of Pap smear screening has been crucial for early detection and intervention, given that over 90% of cervical cancer cases are linked to HPV. Furthermore, emerging cell-based immunotherapies and targeted therapies are expanding the treatment arsenal.
This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the drug class, histology type, distribution channel, age group, and geography.
By Drug Class
By Histology Type
Squamous Cell Carcinoma (SCC)
By Distribution Channel
Hospital & Clinics
Retail & Specialty Pharmacies
By Age Group
Below 29 Years
North America – US
Europe – Germany, France, UK, Italy, Spain
APAC – China, Japan
The global market for cervical cancer therapeutics can be categorized into two main segments based on drug class: chemotherapy and targeted therapy. Among these segments, chemotherapeutic drugs are projected to hold the largest share in the global market for cervical cancer therapeutics. However, it is anticipated that targeted therapies will exhibit the highest growth rate.
Chemotherapy has traditionally been the primary treatment option for cervical cancer. These drugs work by killing rapidly dividing cancer cells throughout the body. Due to their effectiveness in combating cancer, chemotherapeutic drugs have been widely used in the treatment of cervical cancer. As a result, they are expected to continue dominating the global market for cervical cancer therapeutics.
On the other hand, targeted therapies are anticipated to experience rapid growth in the market. This growth can be attributed to the recent approvals of Keytruda and Tivdak, two targeted therapy drugs specifically designed for the treatment of cervical cancer. Keytruda, a PD-1 inhibitor, has shown promising results in clinical trials and has been approved for use in advanced cervical cancer cases. Tivdak, a tyrosine kinase inhibitor, has also received approval for the treatment of advanced cervical cancer. These approvals have significantly contributed to the growth potential of targeted therapies in the market.
Targeted therapies offer a more precise and targeted approach to treating cancer by specifically targeting cancer cells or their supporting structures. This approach minimizes damage to healthy cells and reduces the side effects associated with traditional chemotherapy. The effectiveness and potential benefits of targeted therapies have generated considerable interest among healthcare professionals and patients alike, leading to their projected growth in the market.
In addition to being segmented by drug class, the cervical cancer therapeutics market can also be further categorized based on histology type, namely squamous cell carcinoma (SCC), adenocarcinoma, and mixed histology. Among these histology types, squamous cell carcinoma is projected to hold a significant share in the market. However, it is the adenocarcinoma segment that is expected to exhibit the highest growth rate. This growth can be attributed to the aggressive nature of adenocarcinoma.
Squamous cell carcinoma has historically been the most common histology type of cervical cancer. It arises from the squamous cells lining the cervix and accounts for a substantial portion of cervical cancer cases. Due to its prevalence, squamous cell carcinoma is expected to maintain a significant share in the cervical cancer therapeutics market.
On the other hand, adenocarcinoma, which originates from the glandular cells of the cervix, is anticipated to be the fastest-growing segment in the market. Adenocarcinoma is known for its aggressive behavior and has been associated with a poorer prognosis compared to squamous cell carcinoma. The rapid growth of the adenocarcinoma segment can be attributed to the increasing incidence of this histology type and the need for effective therapeutic interventions to address its aggressiveness.
Furthermore, the cervical cancer therapeutics market can be segmented based on age groups, specifically below 29 years, 30-49 years, and 50+ years. Among these age groups, women aged 50 and above are expected to hold a significant portion of the market share. However, it is the segment of women aged 30-49 years that is projected to be the fastest-growing.
Women aged 50 and above are a crucial demographic in the cervical cancer therapeutics market due to their increased susceptibility to developing cervical cancer as they age. Regular screenings and effective therapeutic interventions are essential for this age group, as early detection and treatment play a vital role in improving outcomes.
Conversely, the segment of women aged 30-49 years is anticipated to experience the highest growth rate in the market. This age group represents women in their reproductive years, and they may face unique challenges and considerations when it comes to cervical cancer. Factors such as increased awareness about the importance of regular screenings, advancements in therapeutic options, and the desire to maintain reproductive health contribute to the projected growth of this segment.
The cervical cancer therapeutics market is divided into two main distribution channels: hospital and clinics, and retail and specialty pharmacies. Among these channels, it is expected that retail and specialty pharmacy services will have a dominant presence. This is primarily due to managed care organizations entering into contracts with specialty providers. These contracts enable managed care organizations to ensure access to specialized cervical cancer therapeutics for their members.
Presently, the United States stands as the frontrunner in the cervical cancer therapeutics market. This can be attributed to several factors, including advanced healthcare infrastructure, extensive research and development activities, and a high prevalence of cervical cancer cases. The United States has made significant strides in the development of innovative therapies and drugs, leading to improved patient outcomes and a higher demand for cervical cancer therapeutics.
However, it is important to note that China is poised to experience rapid growth in the cervical cancer therapeutics market. China, with its large population and increasing healthcare expenditure, presents a significant market opportunity. The country has been witnessing a rise in the incidence of cervical cancer, which has prompted increased focus on the development and adoption of effective therapeutics. Furthermore, China has been investing heavily in healthcare infrastructure and research initiatives, fostering an environment conducive to the growth of the cervical cancer therapeutics market.
Prominent players in the cervical cancer treatment market include Advenchen Laboratories, LLC., Agenus Inc., Akeso, Inc., AstraZeneca plc, BeiGene, Ltd., BioAtla Inc., Clovis Oncology, Inc., Exelixis, Inc., F. Hoffmann-La Roche AG, Genmab A/S, Genor Biopharma Company Ltd., GSK plc, Helsinn Healthcare SA, Incyte Corporation, Innovent Biologics, Inc., Iovance Biotherapeutics, Inc., Jiangsu Hengrui Pharmaceuticals Co., Ltd., JSC BIOCAD, Lee’s Pharmaceutical Holdings Limited/Sorrento Therapeutics, Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology, Inc., Qilu Pharmaceutical Co., Ltd., Sanofi SA/Regeneron Pharmaceuticals, Inc., Seagen Inc., Shanghai Henlius Biotech Inc (Henlius), Takeda Pharmaceutical Company Limited, Zeria Pharmaceutical Co., Ltd., among others. These companies are actively involved in research and development to create advanced and innovative cervical cancer drugs, as well as forming collaborations to maintain their market position.
Scope of the Report
To analyze and forecast the market size of the global cervical cancer therapeutics market.
To classify and forecast the global cervical cancer therapeutics market based on drug class, histology type, distribution channel, age group, geography.
To identify drivers and challenges for the global cervical cancer therapeutics market.
To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global cervical cancer therapeutics market.
To identify and analyze the profile of leading players operating in the global cervical cancer therapeutics market.
Why Choose This Report
Gain a reliable outlook of the global cervical cancer therapeutics market forecasts from 2023 to 2029 across scenarios.
Identify growth segments for investment.
Stay ahead of competitors through company profiles and market data.
The market estimate for ease of analysis across scenarios in Excel format.
Strategy consulting and research support for three months.
Print authentication provided for the single-user license.
Global Cervical Cancer Therapeutics Market 2023 - Report Scope
|Market Size (2022)
USD 5.66 Billion
Drug Class, Histology Type, Distribution Channel, Age Group, Geography
Advenchen Laboratories LLC., Agenus Inc., Akeso Inc., AstraZeneca plc, BeiGene Ltd., BioAtla Inc., Clovis Oncology Inc., Exelixis Inc., F. Hoffmann-La Roche AG, Genmab A/S, Genor Biopharma Company Ltd., GSK plc, Helsinn Healthcare SA, Incyte Corporation, Innovent Biologics Inc., Iovance Biotherapeutics Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., JSC BIOCAD, Lee's Pharmaceutical Holdings Limited/Sorrento Therapeutics Inc., Merck KGaA, Novartis AG, Pfizer Inc., Puma Biotechnology Inc., Qilu Pharmaceutical Co. Ltd., Sanofi SA/Regeneron Pharmaceuticals Inc., Seagen Inc., Shanghai Henlius Biotech Inc (Henlius), Takeda Pharmaceutical Company Limited, Zeria Pharmaceutical Co. Ltd.